Topalian et al.34 have demonstrated that PD-1 blockade is a particularly effective immunotherapy approach in which the cumulative response rates (all doses) are 18% among patients with non-small cell lung cancer (NSCLC), 28% among patients with melanoma, and 27% among patients with renal-cell cancer. Here, PDCD1 is linked to non-small cell lung carcinoma.